Financial Contrast: Artivion (NYSE:AORT) versus Globus Medical (NYSE:GMED)

Globus Medical (NYSE:GMED) and Artivion (NYSE:AORT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Insider & Institutional Ownership

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 6.3% of Artivion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Globus Medical and Artivion”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94 billion	3.42	$537.87 million	$4.07	18.39
Artivion	$441.33 million	2.23	$9.77 million	($0.36)	-56.01

Globus Medical has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Globus Medical and Artivion, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0	6	8	2	2.75
Artivion	1	0	6	0	2.71

Globus Medical presently has a consensus target price of $96.08, suggesting a potential upside of 28.39%. Artivion has a consensus target price of $39.00, suggesting a potential upside of 93.40%. Given Artivion’s higher possible upside, analysts clearly believe Artivion is more favorable than Globus Medical.

Profitability

This table compares Globus Medical and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Artivion	-0.67%	6.07%	2.93%

Volatility & Risk

Globus Medical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Summary

Globus Medical beats Artivion on 13 of the 15 factors compared between the two stocks.

About Globus Medical

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

About Artivion

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.